InventisBio

About InventisBio

InventisBio is a clinical-stage biotechnology company founded in 2013, focusing on the research and development of small molecule drugs for significant unmet medical needs. The company was co-founded by Dr. Yaolin Wang, who serves as Chairman and CEO, and other senior scientists with extensive experience from major pharmaceutical firms like Merck and Schering-Plough. Dr. Wang holds a Ph.D. in Pharmacology from the State University of New York at Stony Brook and has over two decades of experience in preclinical oncology drug discovery. This deep industry background has shaped the company's strategy of developing proprietary drugs for both the Chinese and global markets.

The company's business model is centered on the in-house discovery and clinical development of a pipeline of drug candidates. InventisBio's primary therapeutic areas are oncology and metabolic diseases, targeting conditions such as non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, and gout. The company generates revenue through out-licensing agreements and future product sales. A notable partnership includes out-licensing the China rights for its third-generation EGFR-T790M inhibitor, BPI-D0316, to Betta Pharma. The company operates in the global biopharmaceutical market, with headquarters in Shanghai and operations in the US.

InventisBio has built a robust pipeline of targeted therapies. One of its key products, Garsorasib (D-1553), is a KRAS G12C inhibitor for treating solid tumors, including NSCLC and colorectal cancer. Another significant candidate is D-0502, an oral selective estrogen receptor degrader (SERD) for hormone receptor-positive breast cancer. The company is also advancing D-0120 for gout and hyperuricemia. These products are progressing through various stages of clinical trials in China and the United States. The company's strategy involves seeking market authorization and then commercializing these treatments to provide new options for patients.

The company has achieved significant financial milestones, including a Series D funding round of $147 million in 2020, led by GL Ventures. This was followed by an IPO on the Shanghai STAR Market in July 2022, raising approximately $296 million to fund further research and development. These financial steps underscore investor confidence in InventisBio's R&D platform and pipeline. The company has received market authorization in China for its KRAS G12C inhibitor, Anfangning (Garsorasib), marking a critical step towards commercialization.